Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association

Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. To prepare for future cardiovascular care needs, the American Heart Association deve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2011-03, Vol.123 (8), p.933-944
Hauptverfasser: HEIDENREICH, Paul A, TROGDON, Justin G, LLOYD-JONES, Donald M, NELSON, Sue A, NICHOL, Graham, ORENSTEIN, Diane, WILSON, Peter W. F, JOSEPH WOO, Y, KHAVJOU, Olga A, BUTLER, Javed, DRACUP, Kathleen, EZEKOWITZ, Michael D, ANDREW FINKELSTEIN, Eric, YULING HONG, CLAIBORNE JOHNSTON, S, KHERA, Amit
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 944
container_issue 8
container_start_page 933
container_title Circulation (New York, N.Y.)
container_volume 123
creator HEIDENREICH, Paul A
TROGDON, Justin G
LLOYD-JONES, Donald M
NELSON, Sue A
NICHOL, Graham
ORENSTEIN, Diane
WILSON, Peter W. F
JOSEPH WOO, Y
KHAVJOU, Olga A
BUTLER, Javed
DRACUP, Kathleen
EZEKOWITZ, Michael D
ANDREW FINKELSTEIN, Eric
YULING HONG
CLAIBORNE JOHNSTON, S
KHERA, Amit
description Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.
doi_str_mv 10.1161/CIR.0b013e31820a55f5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_860399000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>860399000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-302d503c193a9483d95d7b69a0afc19427bd620e406e51ebcb2e08b8ed515dab3</originalsourceid><addsrcrecordid>eNpdkcFu1DAQhi1ERZfCGyDkC-KUMrbjbMxttWXbSpVaFXqOJvYEjJK42A5SD7w7bncBidNoRt8_I33D2BsBp0I04sP28vYUehCKlGgloNaDfsZWQsu6qrUyz9kKAEy1VlIes5cpfS9to9b6BTuWQjbSGFixX7sQyWLKfv7K8zfiuyUvkXgY-Baj8-EnJruMGPmZT4SJuJ-fuLvZZ3L8c8ZM6SPf8JswevuwH0w0Z76LYXpCNxNFb3HmF4Qx801KwXrMPsyv2NGAY6LXh3rC7nafvmwvqqvr88vt5qqystW5UiCdBmWFUWjqVjmj3bpvDAIOZVjLde8aCVRDQ1pQb3tJ0PYtOS20w16dsPf7vfcx_Fgo5W7yydI44kxhSV3bgCo6AApZ70kbQ0qRhu4--gnjQyege_TeFe_d_95L7O3hwNJP5P6G_oguwLsDUHziOEScrU__OGVk-U6rfgPe-Iz1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860399000</pqid></control><display><type>article</type><title>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>HEIDENREICH, Paul A ; TROGDON, Justin G ; LLOYD-JONES, Donald M ; NELSON, Sue A ; NICHOL, Graham ; ORENSTEIN, Diane ; WILSON, Peter W. F ; JOSEPH WOO, Y ; KHAVJOU, Olga A ; BUTLER, Javed ; DRACUP, Kathleen ; EZEKOWITZ, Michael D ; ANDREW FINKELSTEIN, Eric ; YULING HONG ; CLAIBORNE JOHNSTON, S ; KHERA, Amit</creator><creatorcontrib>HEIDENREICH, Paul A ; TROGDON, Justin G ; LLOYD-JONES, Donald M ; NELSON, Sue A ; NICHOL, Graham ; ORENSTEIN, Diane ; WILSON, Peter W. F ; JOSEPH WOO, Y ; KHAVJOU, Olga A ; BUTLER, Javed ; DRACUP, Kathleen ; EZEKOWITZ, Michael D ; ANDREW FINKELSTEIN, Eric ; YULING HONG ; CLAIBORNE JOHNSTON, S ; KHERA, Amit ; Council on Cardiovascular Nursing ; Council on Cardiopulmonary ; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research ; Council on Epidemiology and Prevention ; Council on Arteriosclerosis ; Critical Care ; Council on Clinical Cardiology ; American Heart Association Advocacy Coordinating Committee ; Stroke Council ; Council on the Kidney in Cardiovascular Disease ; Council on Cardiovascular Radiology and Intervention ; Thrombosis and Vascular Biology ; Perioperative and Resuscitation</creatorcontrib><description>Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIR.0b013e31820a55f5</identifier><identifier>PMID: 21262990</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>American Heart Association ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular Diseases - economics ; Cardiovascular Diseases - epidemiology ; Coronary Disease - economics ; Coronary Disease - epidemiology ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Forecasting - methods ; Health Care Costs - trends ; Heart Failure - economics ; Heart Failure - epidemiology ; Humans ; Hypertension - economics ; Hypertension - epidemiology ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Policy ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Stroke - economics ; Stroke - epidemiology ; United States - epidemiology</subject><ispartof>Circulation (New York, N.Y.), 2011-03, Vol.123 (8), p.933-944</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c285t-302d503c193a9483d95d7b69a0afc19427bd620e406e51ebcb2e08b8ed515dab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,3674,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23920068$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21262990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HEIDENREICH, Paul A</creatorcontrib><creatorcontrib>TROGDON, Justin G</creatorcontrib><creatorcontrib>LLOYD-JONES, Donald M</creatorcontrib><creatorcontrib>NELSON, Sue A</creatorcontrib><creatorcontrib>NICHOL, Graham</creatorcontrib><creatorcontrib>ORENSTEIN, Diane</creatorcontrib><creatorcontrib>WILSON, Peter W. F</creatorcontrib><creatorcontrib>JOSEPH WOO, Y</creatorcontrib><creatorcontrib>KHAVJOU, Olga A</creatorcontrib><creatorcontrib>BUTLER, Javed</creatorcontrib><creatorcontrib>DRACUP, Kathleen</creatorcontrib><creatorcontrib>EZEKOWITZ, Michael D</creatorcontrib><creatorcontrib>ANDREW FINKELSTEIN, Eric</creatorcontrib><creatorcontrib>YULING HONG</creatorcontrib><creatorcontrib>CLAIBORNE JOHNSTON, S</creatorcontrib><creatorcontrib>KHERA, Amit</creatorcontrib><creatorcontrib>Council on Cardiovascular Nursing</creatorcontrib><creatorcontrib>Council on Cardiopulmonary</creatorcontrib><creatorcontrib>Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research</creatorcontrib><creatorcontrib>Council on Epidemiology and Prevention</creatorcontrib><creatorcontrib>Council on Arteriosclerosis</creatorcontrib><creatorcontrib>Critical Care</creatorcontrib><creatorcontrib>Council on Clinical Cardiology</creatorcontrib><creatorcontrib>American Heart Association Advocacy Coordinating Committee</creatorcontrib><creatorcontrib>Stroke Council</creatorcontrib><creatorcontrib>Council on the Kidney in Cardiovascular Disease</creatorcontrib><creatorcontrib>Council on Cardiovascular Radiology and Intervention</creatorcontrib><creatorcontrib>Thrombosis and Vascular Biology</creatorcontrib><creatorcontrib>Perioperative and Resuscitation</creatorcontrib><title>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.</description><subject>American Heart Association</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Diseases - economics</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Coronary Disease - economics</subject><subject>Coronary Disease - epidemiology</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Forecasting - methods</subject><subject>Health Care Costs - trends</subject><subject>Heart Failure - economics</subject><subject>Heart Failure - epidemiology</subject><subject>Humans</subject><subject>Hypertension - economics</subject><subject>Hypertension - epidemiology</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Policy</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Stroke - economics</subject><subject>Stroke - epidemiology</subject><subject>United States - epidemiology</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkcFu1DAQhi1ERZfCGyDkC-KUMrbjbMxttWXbSpVaFXqOJvYEjJK42A5SD7w7bncBidNoRt8_I33D2BsBp0I04sP28vYUehCKlGgloNaDfsZWQsu6qrUyz9kKAEy1VlIes5cpfS9to9b6BTuWQjbSGFixX7sQyWLKfv7K8zfiuyUvkXgY-Baj8-EnJruMGPmZT4SJuJ-fuLvZZ3L8c8ZM6SPf8JswevuwH0w0Z76LYXpCNxNFb3HmF4Qx801KwXrMPsyv2NGAY6LXh3rC7nafvmwvqqvr88vt5qqystW5UiCdBmWFUWjqVjmj3bpvDAIOZVjLde8aCVRDQ1pQb3tJ0PYtOS20w16dsPf7vfcx_Fgo5W7yydI44kxhSV3bgCo6AApZ70kbQ0qRhu4--gnjQyege_TeFe_d_95L7O3hwNJP5P6G_oguwLsDUHziOEScrU__OGVk-U6rfgPe-Iz1</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>HEIDENREICH, Paul A</creator><creator>TROGDON, Justin G</creator><creator>LLOYD-JONES, Donald M</creator><creator>NELSON, Sue A</creator><creator>NICHOL, Graham</creator><creator>ORENSTEIN, Diane</creator><creator>WILSON, Peter W. F</creator><creator>JOSEPH WOO, Y</creator><creator>KHAVJOU, Olga A</creator><creator>BUTLER, Javed</creator><creator>DRACUP, Kathleen</creator><creator>EZEKOWITZ, Michael D</creator><creator>ANDREW FINKELSTEIN, Eric</creator><creator>YULING HONG</creator><creator>CLAIBORNE JOHNSTON, S</creator><creator>KHERA, Amit</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</title><author>HEIDENREICH, Paul A ; TROGDON, Justin G ; LLOYD-JONES, Donald M ; NELSON, Sue A ; NICHOL, Graham ; ORENSTEIN, Diane ; WILSON, Peter W. F ; JOSEPH WOO, Y ; KHAVJOU, Olga A ; BUTLER, Javed ; DRACUP, Kathleen ; EZEKOWITZ, Michael D ; ANDREW FINKELSTEIN, Eric ; YULING HONG ; CLAIBORNE JOHNSTON, S ; KHERA, Amit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-302d503c193a9483d95d7b69a0afc19427bd620e406e51ebcb2e08b8ed515dab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>American Heart Association</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Diseases - economics</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Coronary Disease - economics</topic><topic>Coronary Disease - epidemiology</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Forecasting - methods</topic><topic>Health Care Costs - trends</topic><topic>Heart Failure - economics</topic><topic>Heart Failure - epidemiology</topic><topic>Humans</topic><topic>Hypertension - economics</topic><topic>Hypertension - epidemiology</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Policy</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Stroke - economics</topic><topic>Stroke - epidemiology</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HEIDENREICH, Paul A</creatorcontrib><creatorcontrib>TROGDON, Justin G</creatorcontrib><creatorcontrib>LLOYD-JONES, Donald M</creatorcontrib><creatorcontrib>NELSON, Sue A</creatorcontrib><creatorcontrib>NICHOL, Graham</creatorcontrib><creatorcontrib>ORENSTEIN, Diane</creatorcontrib><creatorcontrib>WILSON, Peter W. F</creatorcontrib><creatorcontrib>JOSEPH WOO, Y</creatorcontrib><creatorcontrib>KHAVJOU, Olga A</creatorcontrib><creatorcontrib>BUTLER, Javed</creatorcontrib><creatorcontrib>DRACUP, Kathleen</creatorcontrib><creatorcontrib>EZEKOWITZ, Michael D</creatorcontrib><creatorcontrib>ANDREW FINKELSTEIN, Eric</creatorcontrib><creatorcontrib>YULING HONG</creatorcontrib><creatorcontrib>CLAIBORNE JOHNSTON, S</creatorcontrib><creatorcontrib>KHERA, Amit</creatorcontrib><creatorcontrib>Council on Cardiovascular Nursing</creatorcontrib><creatorcontrib>Council on Cardiopulmonary</creatorcontrib><creatorcontrib>Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research</creatorcontrib><creatorcontrib>Council on Epidemiology and Prevention</creatorcontrib><creatorcontrib>Council on Arteriosclerosis</creatorcontrib><creatorcontrib>Critical Care</creatorcontrib><creatorcontrib>Council on Clinical Cardiology</creatorcontrib><creatorcontrib>American Heart Association Advocacy Coordinating Committee</creatorcontrib><creatorcontrib>Stroke Council</creatorcontrib><creatorcontrib>Council on the Kidney in Cardiovascular Disease</creatorcontrib><creatorcontrib>Council on Cardiovascular Radiology and Intervention</creatorcontrib><creatorcontrib>Thrombosis and Vascular Biology</creatorcontrib><creatorcontrib>Perioperative and Resuscitation</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HEIDENREICH, Paul A</au><au>TROGDON, Justin G</au><au>LLOYD-JONES, Donald M</au><au>NELSON, Sue A</au><au>NICHOL, Graham</au><au>ORENSTEIN, Diane</au><au>WILSON, Peter W. F</au><au>JOSEPH WOO, Y</au><au>KHAVJOU, Olga A</au><au>BUTLER, Javed</au><au>DRACUP, Kathleen</au><au>EZEKOWITZ, Michael D</au><au>ANDREW FINKELSTEIN, Eric</au><au>YULING HONG</au><au>CLAIBORNE JOHNSTON, S</au><au>KHERA, Amit</au><aucorp>Council on Cardiovascular Nursing</aucorp><aucorp>Council on Cardiopulmonary</aucorp><aucorp>Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research</aucorp><aucorp>Council on Epidemiology and Prevention</aucorp><aucorp>Council on Arteriosclerosis</aucorp><aucorp>Critical Care</aucorp><aucorp>Council on Clinical Cardiology</aucorp><aucorp>American Heart Association Advocacy Coordinating Committee</aucorp><aucorp>Stroke Council</aucorp><aucorp>Council on the Kidney in Cardiovascular Disease</aucorp><aucorp>Council on Cardiovascular Radiology and Intervention</aucorp><aucorp>Thrombosis and Vascular Biology</aucorp><aucorp>Perioperative and Resuscitation</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>123</volume><issue>8</issue><spage>933</spage><epage>944</epage><pages>933-944</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>21262990</pmid><doi>10.1161/CIR.0b013e31820a55f5</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2011-03, Vol.123 (8), p.933-944
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_860399000
source Journals@Ovid Ovid Autoload; MEDLINE; American Heart Association Journals; EZB-FREE-00999 freely available EZB journals
subjects American Heart Association
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular Diseases - economics
Cardiovascular Diseases - epidemiology
Coronary Disease - economics
Coronary Disease - epidemiology
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Forecasting - methods
Health Care Costs - trends
Heart Failure - economics
Heart Failure - epidemiology
Humans
Hypertension - economics
Hypertension - epidemiology
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Policy
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Stroke - economics
Stroke - epidemiology
United States - epidemiology
title Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A59%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Forecasting%20the%20Future%20of%20Cardiovascular%20Disease%20in%20the%20United%20States:%20A%20Policy%20Statement%20From%20the%20American%20Heart%20Association&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=HEIDENREICH,%20Paul%20A&rft.aucorp=Council%20on%20Cardiovascular%20Nursing&rft.date=2011-03-01&rft.volume=123&rft.issue=8&rft.spage=933&rft.epage=944&rft.pages=933-944&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/CIR.0b013e31820a55f5&rft_dat=%3Cproquest_cross%3E860399000%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=860399000&rft_id=info:pmid/21262990&rfr_iscdi=true